
Therapeutic cancer vaccine
CIMAvax-EGF
It makes the body produce antibodies against its own growth factor (EGF). This weakens a signal that drives the tumour to grow.
- Who it is for
- Advanced (stage IIIB/IV) non-small cell lung cancer that has not progressed after first treatment.
- How it is given
- Into the muscle. The schedule is set by the treating specialists.
- Licence
- First licensed in Cuba in 2008 by the Cuban regulator CECMED. Its licensing status in other countries differs and can change over time.









